meRfi®-GM
The Digital Textbook on Gut Microbiota and Beyond
Breast Cancer / Mammacarcinoma (TNBC)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Mammacarcinoma (triple negative TNBC) is the most aggressive type of Breast Cancer / Mammacarcinoma
Stage I–III triple-negative breast cancer accounts for approximately 15–20% of new diagnoses of early breast cancer
Triple-negative breast cancer (TNBC) is a highly heterogeneous and aggressive malignancy. Characteristic is the absence of Estrogen receptors and [Progesterone receptors](brai…
References (Sources)
- Emerging PARP inhibitors for treating breast cancer
- How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.
- KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
- Research progress on immunotherapy in triple‑negative breast cancer (Review)